BLINCYTO (Blinatumomab)
Bispecific T-Cell Engager Antibody for Acute Lymphoblastic Leukemia
Quick facts about BLINCYTO
Key Takeaways
- BLINCYTO is a first-in-class bispecific T-cell engager (BiTE) antibody that redirects the patient's own immune system to attack leukemia cells
- Approved for relapsed/refractory B-cell precursor ALL, MRD-positive ALL, and consolidation therapy in adults and children
- Administered as continuous intravenous infusion over 4 weeks, requiring initial hospitalization for monitoring
- Major risks include cytokine release syndrome (CRS), neurological toxicity (ICANS), and serious infections requiring close medical supervision
- Treatment decisions and dosage are individualized based on patient weight, disease status, and tolerability
What Is BLINCYTO and What Is It Used For?
BLINCYTO contains the active substance blinatumomab, which belongs to a class of anticancer medicines known as bispecific T-cell engagers (BiTE). Unlike traditional chemotherapy, which directly kills dividing cells, BLINCYTO harnesses the power of the patient's own immune system by creating a bridge between T cells (immune cells) and cancer cells. This innovative mechanism of action represents a significant advance in the treatment of acute lymphoblastic leukemia.
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the blood in which a particular type of white blood cell called B lymphocytes proliferates uncontrollably. These malignant cells crowd out normal blood cells, leading to anemia, increased susceptibility to infections, and bleeding problems. ALL is the most common childhood cancer but also affects adults, with treatment outcomes historically poorer in older patients and those with relapsed disease.
Blinatumomab works by simultaneously binding to CD19, a protein found on the surface of B-lineage cells (including leukemia cells), and to CD3, a protein on the surface of T cells. By bridging these two cell types together, blinatumomab activates the T cell and directs it to kill the CD19-positive leukemia cell. This targeted approach can be highly effective even when conventional chemotherapy has failed.
Approved Indications
BLINCYTO is approved for the following uses in adults, adolescents, and children:
- Relapsed or refractory B-cell precursor ALL: When leukemia has returned after previous treatment (relapsed) or has not responded to treatment (refractory). This represents the original and most established indication for blinatumomab.
- MRD-positive B-cell precursor ALL: When small numbers of cancer cells remain detectable after initial treatment (minimal residual disease, or MRD). MRD positivity is associated with a significantly higher risk of relapse, and blinatumomab can help eliminate these residual cells.
- Consolidation therapy: As part of a multi-phase treatment plan, BLINCYTO may be used during the consolidation phase of ALL treatment to eliminate any remaining leukemia cells after the initial induction phase. This approach aims to deepen the response and improve long-term outcomes.
Clinical trials have demonstrated that blinatumomab can achieve complete remission in a significant proportion of patients with relapsed or refractory ALL, and can convert MRD-positive patients to MRD-negative status, which is associated with improved survival outcomes. The TOWER trial, a landmark phase 3 study, showed that blinatumomab significantly improved overall survival compared to standard chemotherapy in adults with relapsed or refractory B-cell precursor ALL.
What Should You Know Before Taking BLINCYTO?
Contraindications
BLINCYTO must not be used in the following situations:
- Hypersensitivity: If you are allergic to blinatumomab or any of the other ingredients in BLINCYTO (citric acid monohydrate, trehalose dihydrate, lysine hydrochloride, polysorbate 80, sodium hydroxide, or water for injections).
- Breastfeeding: BLINCYTO must not be used during breastfeeding. It is not known whether blinatumomab is excreted in human breast milk, and a risk to the nursing infant cannot be excluded.
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before using BLINCYTO if any of the following apply to you. BLINCYTO may not be suitable, or you may require special monitoring:
If you have ever had neurological problems such as tremor, sensory disturbances, seizures, memory loss, confusion, disorientation, balance problems, or difficulty speaking, inform your healthcare provider. If leukemia has spread to the brain and/or spinal cord, this must be treated before starting BLINCYTO. Your doctor will examine your nervous system and perform tests before deciding whether you should receive BLINCYTO.
- Active infections: Any ongoing infection must be addressed before treatment, as BLINCYTO affects the immune system and can worsen infections or make you more susceptible to new ones.
- Previous infusion reactions: If you have previously experienced an infusion reaction with BLINCYTO, symptoms of which may include wheezing, flushing, facial swelling, difficulty breathing, or changes in blood pressure.
- Vaccinations: Certain vaccines must not be given within two weeks before, during, or in the months following BLINCYTO treatment. Live vaccines are particularly dangerous while your immune system is compromised. Your doctor will determine which vaccinations, if any, are appropriate.
- Neurological effects (ICANS): Confusion, reduced alertness, difficulty speaking or writing. These can be signs of immune effector cell-associated neurotoxicity syndrome (ICANS).
- Seizures, slurred speech, disorientation, or balance problems
- Signs of infection: Chills, rigors, or fever
- Infusion reactions: Dizziness, faintness, nausea, facial swelling, difficulty breathing, wheezing, or rash
- Severe abdominal pain (with or without nausea and vomiting) which may indicate pancreatitis
- HLH/IEC-HS symptoms: Fever, swollen lymph nodes, breathing problems, easy bruising or bleeding, enlarged liver or spleen
Patients with Down syndrome may have a higher risk of seizures during BLINCYTO treatment and may be given anti-seizure medication before treatment begins.
Before each infusion with BLINCYTO, you will receive medications to help minimize a potentially life-threatening complication called tumor lysis syndrome (TLS). This syndrome results from chemical disturbances in the blood caused by the breakdown of dying cancer cells. You may also receive medications to reduce fever.
During treatment, and particularly during the very first days after starting, you may experience a serious decrease in white blood cell count (neutropenia), serious decrease in white blood cells with fever (febrile neutropenia), elevated liver enzymes, or elevated uric acid levels. Your doctor will perform regular blood tests to monitor your blood cell counts throughout treatment.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or nurse for advice before using this medicine.
Contraception: Women of childbearing potential must use effective contraception during treatment and for at least 48 hours after the last treatment dose. Discuss suitable contraceptive methods with your healthcare provider.
Pregnancy: The effects of BLINCYTO on pregnant women are not known. However, based on the mechanism of action of blinatumomab, it could potentially harm the unborn baby by depleting fetal B cells. BLINCYTO should not be used during pregnancy unless your doctor considers it the best medicine for you. If you become pregnant during treatment, tell your doctor or nurse immediately. Your doctor will discuss precautions regarding vaccinations for the baby.
Breastfeeding: You must not breastfeed during treatment and for at least 48 hours after your last treatment dose. It is not known whether blinatumomab is excreted in breast milk, but a risk to the nursing infant cannot be excluded.
Driving and Using Machines
You should not drive, use heavy machinery, or participate in hazardous activities while receiving BLINCYTO. This medicine can cause neurological problems such as dizziness, seizures, confusion, and coordination and balance disturbances that may impair your ability to perform these activities safely.
How Does BLINCYTO Interact with Other Drugs?
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines. While formal drug-drug interaction studies have not been conducted with blinatumomab, several clinically important considerations apply when using BLINCYTO alongside other medications.
The initiation of BLINCYTO treatment causes transient release of cytokines during the first days of treatment. This cytokine release may suppress CYP450 enzymes, potentially affecting the metabolism of other drugs that are substrates of these enzymes. Patients receiving concomitant CYP450 substrates with a narrow therapeutic index (such as warfarin or cyclosporine) should be monitored closely, as dose adjustments may be needed.
| Drug / Drug Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Live vaccines | Immunological | High | Avoid within 2 weeks before, during, and for months after treatment |
| Corticosteroids (dexamethasone) | Premedication | Required | Given routinely before each cycle to prevent CRS |
| CYP450 substrates (narrow therapeutic index) | Metabolic | Moderate | Monitor levels closely during first cycle; adjust dose as needed |
| Intrathecal chemotherapy | Concomitant use | Standard | May be given before and during treatment to prevent CNS relapse |
| Anticonvulsants | Supportive care | Moderate | May be given prophylactically, especially in patients with Down syndrome or seizure history |
What Is the Correct Dosage of BLINCYTO?
Always use this medicine exactly as your doctor, pharmacist, or nurse has instructed. BLINCYTO is administered via a vein (intravenously) as a continuous infusion over a 4-week period using an infusion pump. This constitutes one treatment cycle. After each 4-week infusion period, there is a 2-week treatment-free interval before the next cycle may begin.
An infusion catheter will be inserted for the entire duration of each treatment cycle. Your doctor will determine when the BLINCYTO infusion bag should be changed, which may vary from every day to every 4th day depending on the prescribed infusion rate. The daily dose of BLINCYTO remains the same regardless of how frequently the bag is changed.
Adults (Body Weight 45 kg or More)
Relapsed or Refractory ALL
| Treatment Phase | Duration | Daily Dose | Administration |
|---|---|---|---|
| Cycle 1, Week 1 | Days 1-7 | 9 μg/day | Continuous IV infusion |
| Cycle 1, Weeks 2-4 | Days 8-28 | 28 μg/day | Continuous IV infusion |
| Treatment-free interval | Days 29-42 | No infusion | 14-day break |
| Subsequent cycles | Days 1-28 | 28 μg/day | Continuous IV infusion |
MRD-Positive ALL and Consolidation Therapy
For patients with MRD-positive ALL or those receiving BLINCYTO as consolidation therapy who weigh 45 kg or more, the dose is 28 micrograms per day throughout all treatment cycles. There is no dose escalation period for these indications, as the risk profile is generally more favorable in patients who have already achieved hematologic remission.
Children and Patients Weighing Less Than 45 kg
For patients weighing less than 45 kg, dosing is based on body surface area (BSA) rather than a fixed dose:
Relapsed or Refractory ALL (Weight < 45 kg)
- Cycle 1, Week 1: 5 μg/m²/day (not to exceed 9 μg/day)
- Cycle 1, Weeks 2-4: 15 μg/m²/day (not to exceed 28 μg/day)
- Subsequent cycles: 15 μg/m²/day (not to exceed 28 μg/day)
MRD-Positive ALL and Consolidation (Weight < 45 kg)
- All cycles: 15 μg/m²/day (not to exceed 28 μg/day)
Experience with BLINCYTO in infants under 1 year of age is limited. The safety of blinatumomab administration for patients with a BSA less than 0.4 m² has not been established.
Treatment Duration
The number of treatment cycles depends on the indication and your response to treatment:
- Relapsed or refractory ALL: Typically 2 treatment cycles. If you respond well, your doctor may give up to 3 additional cycles (maximum 5 cycles total).
- MRD-positive ALL: 1 treatment cycle is standard, with possible additional cycles based on response.
- Consolidation therapy: The number of cycles is determined by your doctor as part of your overall treatment plan.
Hospitalization Requirements
Due to the risk of serious adverse events, hospitalization is recommended during the initial days of treatment:
- Relapsed or refractory ALL: First 9 days of cycle 1 and first 2 days of cycle 2
- MRD-positive ALL: First 3 days of cycle 1 and first 2 days of subsequent cycles
- Consolidation therapy: First 3 days of cycle 1 and first 2 days of cycle 2
- Neurological conditions: First 14 days of treatment if you have or have had neurological problems
After the initial hospitalization period, your doctor will discuss whether you can continue treatment at home. Home treatment may involve a nurse regularly changing the infusion bag.
Infusion Pump and Catheter Care
Never adjust the pump settings yourself, even if there appears to be a problem or the pump alarms. Any changes to pump settings could result in a dose that is too high or too low. Contact your doctor or nurse immediately if:
- There is a problem with the pump or the pump alarms
- The infusion bag empties before the next scheduled bag change
- The infusion pump stops unexpectedly (do not attempt to restart it yourself)
Keeping the area around the catheter clean is critically important to prevent infection. Your doctor or nurse will show you how to care for the catheter properly. The infusion bag is typically changed at infusion rates of 10 ml/hour (24-hour bags), 5 ml/hour (48-hour bags), 3.3 ml/hour (72-hour bags), or 2.5 ml/hour (96-hour bags).
Premedication
Before each BLINCYTO cycle, you will receive premedication to minimize infusion reactions and other potential side effects. This typically includes corticosteroids such as dexamethasone. Additionally, before and during treatment, you may receive intrathecal chemotherapy (injection into the space surrounding the spinal cord and brain) to prevent leukemia relapse in the central nervous system.
Overdose
Overdoses have been observed in clinical experience with BLINCYTO. Signs and symptoms of overdose may be consistent with the known adverse reactions of the drug, including fever, tremor, and headache. In the event of overdose, the infusion should be temporarily interrupted and the patient should be monitored. Restarting at the correct dose should be considered once symptoms have resolved. There is no specific antidote for blinatumomab.
What Are the Side Effects of BLINCYTO?
Like all medicines, BLINCYTO can cause side effects, although not everybody gets them. Some of these side effects can be serious and may require immediate medical attention. Your healthcare team will monitor you closely for signs and symptoms of these reactions throughout your treatment.
- Signs of infection: Chills, rigors, fever, rapid heartbeat, low blood pressure, muscle aches, fatigue, cough, breathing difficulties, confusion, redness, swelling or discharge at the catheter site
- Neurological symptoms (ICANS): Tremor, confusion, encephalopathy (brain function disturbances), communication difficulties (aphasia), seizures
- Cytokine release syndrome (CRS): Fever, swelling, chills, low or high blood pressure, fluid in the lungs
- Severe abdominal pain with or without nausea and vomiting (may indicate pancreatitis)
- HLH/IEC-HS: Fever, enlarged liver/spleen, swollen lymph nodes, breathing problems, easy bruising or bleeding
Side Effect Frequency
Very Common
- Bloodstream infections (bacterial, viral, or other)
- Decreased white blood cells with or without fever (febrile neutropenia, leukopenia)
- Decreased red blood cells (anemia)
- Decreased platelets (thrombocytopenia)
- Cytokine release syndrome (CRS)
- Difficulty sleeping (insomnia)
- Headache, tremor (may indicate ICANS)
- Rapid heartbeat (tachycardia)
- Low blood pressure (hypotension)
- High blood pressure (hypertension)
- Cough
- Nausea, diarrhea, vomiting, constipation, abdominal pain
- Rash
- Back pain, pain in arms and/or legs
- Fever (pyrexia), facial/lip/mouth/throat swelling (edema), chills
- Low immunoglobulin levels
- Elevated liver enzymes (ALT, AST, GGT)
- Infusion-related reactions (wheezing, flushing, facial swelling, breathing difficulties, blood pressure changes)
Common
- Serious infections leading to organ failure, shock, or death (sepsis)
- Pneumonia
- Fungal infections
- Elevated or decreased white blood cell counts (leukocytosis, lymphopenia)
- Allergic reactions
- Tumor lysis syndrome
- Confusion, disorientation, encephalopathy, aphasia, paresthesia (tingling), seizures, cognitive impairment, ataxia, somnolence, numbness, dizziness (ICANS symptoms)
- Cranial nerve disorders (visual disturbances, drooping eyelids, facial weakness, hearing or swallowing difficulties)
- Wheezing or breathing difficulties (dyspnea), respiratory failure
- Hot flashes
- Productive cough
- Elevated bilirubin
- Bone pain, chest pain
- Elevated enzyme levels
- Weight gain
Uncommon
- HLH/IEC-HS (hemophagocytic lymphohistiocytosis) - a potentially life-threatening immune overactivation
- Swollen lymph nodes (lymphadenopathy)
- Cytokine storm (severe, potentially fatal form of CRS)
- Capillary leak syndrome (fluid leakage from small blood vessels)
- Speech or writing difficulties (ICANS-related)
Side Effects More Common in Children and Adolescents
Certain side effects have been observed more frequently in pediatric patients compared to adults:
- Decreased red blood cells (anemia)
- Decreased platelets (thrombocytopenia)
- Decreased certain white blood cells (leukopenia)
- Fever (pyrexia)
- Infusion-related reactions including facial swelling and blood pressure changes
- Weight gain
- High blood pressure (hypertension)
Reporting Side Effects
It is important to report suspected side effects after the medicine has been authorized. This allows continuous monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority.
How Should You Store BLINCYTO?
Keep this medicine out of the sight and reach of children. Do not use after the expiry date stated on the label and carton after EXP. The expiry date refers to the last day of that month.
Unopened Vials
- Store and transport refrigerated at 2°C to 8°C (36°F to 46°F)
- Do not freeze
- Store in the original packaging to protect from light
- Shelf life: 5 years when stored as directed
Reconstituted Solution
- Must be used within 24 hours when stored at 2°C to 8°C
- Alternatively, can be stored at room temperature (up to 27°C / 81°F) for up to 4 hours
- Should be diluted promptly to minimize risk of microbial contamination
Prepared Infusion Bags
If your infusion bag is changed at home:
- Infusion bags come in special packaging containing cold packs
- Do not open the packaging yourself
- Store the packaging at room temperature (up to 27°C / 81°F)
- Do not place the packaging in the refrigerator or freezer
- Your nurse will open the packaging and refrigerate the infusion bag until infusion
- When stored refrigerated, prepared bags must be used within 10 days from preparation
- Once at room temperature (up to 27°C / 81°F), the solution must be infused within 96 hours
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Does BLINCYTO Contain?
BLINCYTO is a powder for concentrate and solution for infusion. Each package contains two components:
- Powder vial: One glass vial containing white to off-white powder with 38.5 micrograms of blinatumomab. Reconstitution with water for injections yields a final concentration of 12.5 micrograms/ml.
- Stabilizer solution vial: One glass vial containing a colorless to slightly yellowish clear solution used during preparation of the infusion bag.
Excipients
| Component | Ingredient | Function |
|---|---|---|
| Powder | Citric acid monohydrate (E330) | Buffer / pH adjustment |
| Powder | Trehalose dihydrate | Stabilizer / cryoprotectant |
| Powder | Lysine hydrochloride | Stabilizer |
| Powder | Polysorbate 80 (E433) | Surfactant |
| Powder | Sodium hydroxide | pH adjustment |
| Stabilizer solution | Citric acid monohydrate, lysine hydrochloride, polysorbate 80, sodium hydroxide, water for injections | Stabilization during infusion preparation |
This medicine contains less than 1 mmol (23 mg) sodium per 24-hour infusion, i.e., it is essentially sodium-free. This is relevant for patients on a sodium-restricted diet.
Frequently Asked Questions About BLINCYTO
BLINCYTO (blinatumomab) is used to treat acute lymphoblastic leukemia (ALL), a type of blood cancer, in adults and children. It is specifically approved for three situations: (1) relapsed or refractory B-cell precursor ALL, where the cancer has come back or not responded to other treatments; (2) MRD-positive ALL, where small amounts of cancer remain after initial treatment; and (3) as consolidation therapy to strengthen the response after initial treatment. BLINCYTO works by redirecting the patient's own immune T cells to attack cancer cells.
BLINCYTO is given as a continuous intravenous infusion that runs 24 hours a day for 4 weeks, using a portable infusion pump. This is followed by a 2-week break, making up one treatment cycle of 6 weeks total. For relapsed or refractory ALL, typically 2 cycles are given with up to 3 additional cycles possible. Patients are usually hospitalized for the first 9 days of the first cycle and the first 2 days of the second cycle. After the initial hospitalization, treatment can often continue at home with nursing support.
Cytokine release syndrome (CRS) is a potentially serious immune reaction that can occur when BLINCYTO activates T cells. Symptoms include fever, chills, low blood pressure, difficulty breathing, and swelling. CRS is most common during the first few days of treatment. To reduce the risk, patients receive premedication with corticosteroids (such as dexamethasone) before each cycle. Patients are also hospitalized during the initial treatment days so that healthcare professionals can monitor for and promptly treat CRS if it occurs. Most cases can be managed with supportive care and, in severe cases, temporary interruption of the infusion.
No, you should not drive, operate heavy machinery, or engage in hazardous activities while receiving BLINCYTO. The medication can cause neurological side effects including dizziness, confusion, seizures, and balance problems that could impair your ability to perform these activities safely. These neurological effects can occur at any time during treatment. Discuss with your healthcare team when it may be safe to resume these activities after treatment is completed.
If you experience any problem with the infusion pump, do not attempt to adjust the settings or restart the pump yourself. Contact your doctor or nurse immediately. Any changes to pump settings could result in receiving too much or too little medication. Specifically, contact your healthcare team if the pump alarms, the bag empties before the scheduled change, or the pump stops unexpectedly. Your healthcare team will provide guidance on managing any pump issues and will take care of any necessary adjustments.
The effects of BLINCYTO on pregnant women are not fully known. Based on its mechanism of action (which targets B cells), BLINCYTO could potentially harm an unborn baby by depleting fetal B cells. Women of childbearing potential should use effective contraception during treatment and for at least 48 hours after the last dose. If you become pregnant during treatment, inform your doctor immediately. BLINCYTO should only be used during pregnancy if your doctor determines the potential benefits outweigh the risks. Breastfeeding is not allowed during treatment and for 48 hours after the last dose.
References
All medical information on this page is based on the following peer-reviewed sources, regulatory documents, and international guidelines:
- European Medicines Agency (EMA). BLINCYTO Summary of Product Characteristics. Last updated November 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/blincyto
- Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836-847. doi:10.1056/NEJMoa1609783
- Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531. doi:10.1182/blood-2017-09-801555
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 2.2025.
- Brown PA, Ji L, Xu X, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):843-854. doi:10.1001/jama.2021.0669
- U.S. Food and Drug Administration (FDA). BLINCYTO Prescribing Information. Reference ID: 5335876.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Acute Lymphoblastic Leukaemia. 2024 Update.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians with expertise in hematology-oncology and clinical pharmacology.
All content follows the GRADE evidence framework and is based on systematic reviews, randomized controlled trials, and international guidelines. We maintain complete editorial independence with no pharmaceutical company funding or sponsorship. For more information, see our editorial standards.